106 results about "Gland cell" patented technology

The present invention relates to a method capable of using natural and artificial synthetic isosulfocyanate compound or its derivative to prevent and cure prostatic diseases and skin carcinoma. The internal tests show that various isosulfocyanate compounds or their derivatives can induce prostatic cell II phase drug metabolic detoxication enzyme-glutathione transferase so as to can inhibit the hyperplasia of prostate and inflammation, and can prevent and cure prostatic carcinoma and skin carcinoma.

The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry.

The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16^INK4A antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.

The invention discloses a method for preparing a rainbow trout IHN (Infectious Haematopoietic Necrosis) inactivated vaccine, which comprises the following steps: carrying out grinding, filtering and poison dipping processing on pancreas and livers of juvenile fish which is attacked, but is still alive, inoculating rainbow trout gonad (RTG) cells, carrying out blind passaging at 14 DEG C, keeping for 5 days when carrying out blind passaging on the tenth generation, and collecting cell poisonous fluid; inoculating chinook salmon embryonic (CHSE) cells, carrying out passaging at 14 DEG C, and raising the culture temperature by 1 DEG C when passaging for 5 generations each time until the culture temperature is raised to 20 DEG C; and adopting epithelioma papulosum cyprini (EPC) cells to continuously carry out passaging under the condition of 20 DEG C, passaging to the twelfth generation to obtain high-titer virus solution and carrying out inactivation to obtain the rainbow trout IHN inactivated vaccine. According to the preparation method, RTG-2, CHSE-214 and EPC cells are utilized to alternately culture rainbow trout IHN viruses at a specific environment temperature so as to obtain a high-titer IHNV (Infectious Hematopoietic Necrosis Virus) antigen and produce the inactivated vaccine; and the technical difficult problem that the high-titer IHNV antigen cannot be obtained through single cells is solved.

The invention relates to a sex development regulation and control technology for the male Chinese mitten crab, in particular to a sex reversal siRNA of the Chinese mitten crab and application of the siRNA. A nucleotide sequence of a positive-sense strand of the sex reversal siRNA of the male Chinese mitten crab is shown in SEQ ID NO.1, and a nucleotide sequence of an antisense strand is shown in SEQ ID NO.2. according to the sex reversal siRNA, an IAG gene segment of the Chinese mitten crab is screened from an androgenic gland transcriptome of the Chinese mitten crab, the total-length cDNA sequence of the segment is cloned, according to an IAG gene sequence of the Chinese mitten crab, the siRNA is designed, synthesized and guided into a body of the Chinese mitten crab in the sex differentiation period, expression of an IAG gene in an androgenic gland cell is disturbed, and sex reversal of the male crab is achieved. Compared with androgenic gland removal through surgery, a micro-injection method is adopted and has the advantages that the trauma to the body of the Chinese mitten crab is small, and the situation is avoided that due to wound infection after surgery, the Chinese mittencrab dies; the injection dose is extremely low, the immunological stress reaction of a tested animal is not easily triggered, and accordingly the success rate of sex reversal is increased.

The present invention relates to the use of a compound of formula (1):

wherein: R1 comprises a carbonyl group and R2 is a hydrocarbyl group; optionally wherein said ring is further substituted; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in one or more of: modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; modulating calcium spikes in mammalian cells; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes by modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; treating diseases in one or more of brain, heart, and T-cells by modulating calcium spikes in mammalian cells.

The invention discloses a composition with acne removing and repairing functions, application of the composition in cosmetics, gel and a preparation method of the gel, and relates to the field of cosmetics. The composition is prepared from salicylic acid, a centella asiatica extract, a white willow extract, 4-terpineol, a chlorella extract, ergothioneine, a pine mushroom extract, a barosma betulina leaf extract and 10-hydroxydecanoic acid. Salicylic acid compounded with the chlorella extract and ergothioneine components is adopted to efficiently balance skin microorganisms; various plant extracts are natural and safe and have mild functions; the 4-terpineol, the white willow bark extract and the like in the formula have remarkable antibacterial and anti-inflammatory effects; the barosma betulina leaf extract, the 10-hydroxydecanoic acid and other extracts can inhibit sebaceous gland cell differentiation to achieve an efficient oil-control effect; and the ergothioneine, the chlorella extract and other extracts have an efficient repairing effect on skin, so that the product has efficient repairing, anti-inflammation and oil control functions, and has a remarkable acne removing effect and high safety.

The invention belongs to the technical field of medical biology, and discloses a molecular marker-LncRNA SNHG11 for auxiliary diagnosis of prostatic cancer. The LncRNA SNHG11 is highly expressed in cancer tissues of prostatic cancer, and is lowly expressed in paracancerous normal tissues; moreover, the expression level of the LncRNA SNHG11 in a prostatic cancer cell line is obviously higher than that of a normal prostate cell line; proliferation, migration and invasion of prostatic cancer cells can be obviously inhibited by knocking down the expression level of the LncRNA SNHG11 gene. Therefore, the LncRNA SNHG11 can be used as a molecular marker for auxiliary diagnosis of the prostatic cancer; by detecting the expression level of the LncRNA SNHG11 in a sample, auxiliary diagnosis can be carried out on the prostatic cancer, and a reference basis is provided for clinical doctors to diagnose the prostatic cancer.

The invention relates the isosulfocyanate compounds (ISOTHIOCYANATES), in other word, JC-5411 compounds, which can adjust the expression of androgen acceptor gene in cell by suppressing the expression of gene transcription factor SP1, and suppress the abnormal breeding function of prostate gland cell. With the little compound, it can suppress hamster benign hypertrophy of the prostate (BPH), which is induced by suppressed male sex hormone, and the growth of prostate gland cancer cell. The invention provides the new method of effectively preventing and treating the hypertrophy of the prostate and prostate gland cancer. The compound possesses the low side effect, steady chemical biology nature, low cost of manufacture, and broad adaptability.

The invention belongs to the technical field of bioengineering and in particular relates to a recombination method and application of a luciferase reporter gene with a human aquaporin 1 (AQP1) promoter to drug screening. The highly expressed AQP1 plays an important role in the salivary secretion process and is closely related to onset of Sjogren syndromes. In the invention, a 1868bp AQP1 promoter sequence is amplified from a personal genome by utilizing the gene engineering technology and is cloned onto a PGL2-luc vector to construct an AQP1 promoter-Luc expression vector. AQP1 expression is controlled by a promoter region. Constructing a salivary gland cell model with the AQP1 promoter is a key step for screening the traditional Chinese medicine ingredients which can treat the Sjogren syndromes. The drug screening cell model proves that ginseng and American ginseng ingredients at certain concentrations can promote transcription of the AQP1 promoter and the higher the concentrations are, the stronger the activity is, and can guide the drugs to be clinically applied to treat the Sjogren syndromes.

The invention relates to an application of deer oil in the preparation of beauty breast cosmetics, and belongs to an application of an economical animal oil in the cosmetic field. The deer oil has functions of skin moistening and breast beautification and enhancement, fundamentally repairs and activates breast gland cells, recultures breast cells, supplement necessary nutrient elements, promotes to increase breast tissues and helps corrects flat chest, microemulsion, breast collapse and depression so as to make breast plump and elastic, make skin soft, smooth and tender, and actually improve mastitis.

The invention discloses an oligopeptide with breast cancer resisting activity. A sequence of the oligopeptide is His-Asn-Tyr-Gly-Phe-Val-Pro-Ser-Leu. The oligopeptide with low concentration also can selectively suppress growth of extracorporeal breast cancer cells and does not affect growth of normal mammary gland cells. Extracorporeal tests also show that the oligopeptide has a high suppression effect for the growth and proliferation of cancer cells, and obvious dose and effect relation is displayed. Owing to the safe, efficient and ideal anti-cancer effect, the oligopeptide can be used for preparing anti-cancer medicines and has a good application prospect.